StockNews.com Begins Coverage on Titan Pharmaceuticals (NASDAQ:TTNP)

Equities researchers at StockNews.com began coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP) in a note issued to investors on Friday. The brokerage set a “sell” rating on the specialty pharmaceutical company’s stock.

Titan Pharmaceuticals Stock Performance

Shares of NASDAQ TTNP opened at $3.52 on Friday. The stock’s fifty day simple moving average is $3.82 and its 200 day simple moving average is $5.09. Titan Pharmaceuticals has a 52-week low of $3.12 and a 52-week high of $14.80.

Titan Pharmaceuticals Company Profile

Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.